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Abstract
Background: Lewy body–related α-synucleinopathy (LBAS, the abnormal accumulation of pathologic α-synuclein) is
found in the central and peripheral nervous systems, including the spinal cord, dorsal root ganglia, and sympathetic
ganglia, of Parkinson’s disease patients. However, few studies have focused on the distribution of LBAS in the spinal
cord, primary sensory neurons, and preganglionic sympathetic nerves.
Results: We analyzed 265 consecutive subjects with LBAS who underwent autopsy at a general geriatric hospital. LBAS
in the spinal cord was significantly associated with that in the lower brainstem regions that are directly connected to
the spinal cord (i.e., the medullary reticular formation and locus ceruleus), but it was not associated with the olfactory
bulb–amygdala system, which is not directly connected to the spinal cord, suggesting that the lower brainstem is a
key structure regarding the spread of LBAS to the spinal cord. In the primary sensory neurons, most subjects with LBAS
in the dorsal root ganglia had LBAS in the dorsal root, and all subjects with LBAS in the dorsal root also had LBAS in
the dorsal horn, suggesting that LBAS spreads retrogradely from the axonal terminals of the dorsal horn to the somata
of the dorsal root ganglia via the dorsal root. In the preganglionic sympathetic nerves, the LBAS in the sympathetic
ganglia preceded that in the nucleus of the intermediolateral column of the thoracic cord, suggesting that LBAS
spreads retrogradely through the preganglionic sympathetic nerves.
Conclusions: LBAS in the spinal cord was associated with the lower regions of the brainstem, but not with the
olfactory bulb or amygdala. LBAS may spread centrifugally along the primary sensory neurons, whereas it may spread
centripetally along the preganglionic sympathetic nerves.
Background
Lewy bodies, neurites and dots are aggregates com-
posed mainly of α-synuclein and are pathological
hallmarks of Lewy body diseases, which include
Parkinson’s disease and dementia with Lewy bodies
[1]. In patients with Lewy body disease, these aggre-
gates are found not only in the brain, but also in the
spinal cord, sympathetic ganglia, and cardiac plexuses
[2–4]. Recent studies have shown that pathologic α-
synuclein may propagate from one cell to another and
spread to different interconnected brain regions [5–15].
Lewy body–related α-synucleinopathy (LBAS, the ab-
normal accumulation of pathologic α-synuclein) in the
brain spreads in a sequential, predictable fashion, that
is, it spreads rostrally from the brainstem in a process
described by the Braak hypothesis [16, 17]. In addition
to this brainstem-ascending pathway, an alternative
pathway, the olfactory bulb–amygdala pathway, has
been reported to be present in up to 30 % of cases of
Lewy body disease [18, 19].
LBAS in the spinal cord may begin to develop in spe-
cific regions such as the dorsal horn, intermediolateral
column of the thoracic cord (Th-IML), and intermedio-
lateral column of the sacral cord (Sa-IML) [20]. So far,
studies investigating LBAS in the spinal cord have only
examined subjects in which the spread of LBAS was
* Correspondence: smurayam@bbarjp.net
1Department of Neuropathology (the Brain Bank for Aging Research), Tokyo
Metropolitan Geriatric Hospital & Institute of Gerontology, 35-2 Sakae-cho,
Itabashi-ku, Tokyo 173-0015, Japan
Full list of author information is available at the end of the article
© 2015 Sumikura et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sumikura et al. Acta Neuropathologica Communications  (2015) 3:57 
DOI 10.1186/s40478-015-0236-9
following the brainstem-ascending pathway of LBAS and
not the olfactory bulb–amygdala pathway [20–22].
Anatomical studies have revealed that, unlike the ol-
factory bulb and the amygdala, the lower brainstem nu-
clei, including the medullary reticular formation, locus
ceruleus, and raphe nucleus, are directly connected to
the spinal gray matter via projecting neurons [23–26].
Little is known about whether the spread of LBAS to
the spinal cord is different in patients in whom the
LBAS is spreading following the brainstem-ascending
pathway compared with those in which it is spreading
following the olfactory bulb–amygdala pathway. Simi-
larly, the distribution of LBAS in the primary sensory
neurons, whose cell bodies are located within the dorsal
root ganglia (DRG) and axons extend into the dorsal
horn via the dorsal root, is yet to be fully examined.
The sympathetic ganglia, which are innervated by the
nucleus of the Th-IML, are known to be where LBAS
manifests in the early phase of the disease process [3].
However the association between LBAS in the sympa-
thetic ganglia and that in the Th-IML is yet to be fully
elucidated.
According to the hypothesis described by Braak and
colleagues [16], the dorsal motor nucleus of the vagus is
one of the first regions in which LBAS develops, suggest-
ing that the pathological process of Lewy body diseases
may begin in the gut. The preganglionic parasympathetic
nerves that innervate the gut are comprised of axons
whose cell bodies are located within the nucleus of the
Sa-IML; however, it is not yet fully understood whether
the Sa-IML is also one of the primary sites in the spinal
cord where LBAS begins to develop.
In the present study, we investigated the distribution
of LBAS in the spinal cord, primary sensory neurons,
and preganglionic sympathetic nerves in a consecutive
autopsy series of elderly subjects.
Materials and methods
Subject selection
Samples of brain and spinal cord were collected from
796 consecutive full autopsies of elderly persons con-
ducted in our institution between January 2003 and July
2013. Paraffin sections of the lumbosacral cord, thoracic
cord, medulla, pons, midbrain, olfactory bulb, amygdala,
hippocampus, cervicothoracic level of the sympathetic
ganglia, heart, esophagus, and brachial skin were pre-
pared and subjected to immunohistochemical analyses.
Of the 796 subjects examined, 265 had LBAS in at least
one of the anatomical regions examined.
Next, paraffin sections of the cervical cord, lumbosa-
cral level of the DRG, and sites stipulated in the third
report of the Dementia with Lewy Bodies Consortium
[27] were analyzed as described below. C8, Th8, L2, L5,
S1, and S2 were evaluated as representative levels of the
spinal cord.
Neuropathological diagnoses were based on the third
report of the Dementia with Lewy Bodies Consortium
[27], our institute’s original criteria [28], Braak staging of
β-amyloid and neurofibrillary tangle formation [29],
Consortium to Establish a Registry for Alzheimer’s Dis-
ease [30], Thal phase evaluation [31], and argyrophilic
grain staging [32].
The relatives’ informed consent was obtained from all
subjects. Our Brain Bank for Aging Research was ap-
proved by the ethics committee of Tokyo Metropolitan
Geriatric Hospital (No. 16).
The following aspects were analyzed in this study:
(A) Presence of LBAS in the spinal cord versus that in
the brain (n = 265).
(B) Presence of LBAS in the spinal cord versus that in
the (both n = 265).
(C) Presence of LBAS in the S2 dorsal horn versus that
in specific regions of the brainstem (medullary
reticular formation or locus ceruleus; n = 261, 260,
respectively) or that in the amygdala (n = 261). The
S2 dorsal horn was selected as the representative
site of the spinal cord because lower level of spinal
cord usually contains the greatest amount of LBAS
deposits [3, 20].
(D)Distribution of LBAS in the primary sensory
neurons at the S2, S1, L5, and L2 levels (n = 261,
46, 261, and 225, respectively).
(E) Presence of LBAS in the Th-IML versus that in the
sympathetic ganglia (n = 222).
(F) Comparison of LBAS density in four different
regions of the spinal cord: dorsal horn (Rexed
lamina I–VI, n = 256), ventral horn (Rexed
lamina VIII–IX, n = 258), intermediate zone
(Rexed lamina VII and X, n = 258), and large
motor neurons in the ventral horn (n = 255).
Identification of large motor neurons was based
on morphological features, including large,
multipolar cell bodies containing large Nissl
bodies.
(G)Confirmation of the presence of LBAS in the Sa-
IML (n = 261).
Histology
At the time of autopsy, half of the brain was preserved
at −80 °C, and the other half was fixed in 20 % neutral-
buffered formalin (WAKO, Osaka, Japan) for 7–13 days
and then sectioned. Representative areas of the brain
and spinal cord were embedded in paraffin and cut seri-
ally into 6-μm–thick sections. For autopsies conducted
prior to April 2011, spinal cords were fixed by using
20 % formalin (226 of 265 subjects with LBAS), whereas
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spinal cords sampled from April 2011 (39 of 265 sub-
jects with LBAS) and peripheral organs were fixed in
4 % paraformaldehyde in 0.1 M phosphate buffer
(pH 7.4) for 48 h. Sections were pretreated with 98 %
formic acid for 5 min. For immunohistochemical ana-
lysis, we used a phosphorylation dependent anti-α-
synuclein monoclonal antibody (pSyn#64; donated by
Dr. Iwatsubo, University of Tokyo), which recognizes
Ser129. Sections were processed with a Ventana Discovery
automatic immunostainer (Roche, Basel, Switzerland).
The diameters of the α-synuclein immunoreactive struc-
tures were measured visually under a light microscope
(Nikon ECLIPSE 80i) with the operator blinded to the
clinical and pathological diagnoses.
Semi-quantitative analysis of LBAS
The degree (density score) of LBAS in the spinal cord,
dorsal root, DRG, and sympathetic ganglia was semi-
quantitatively graded under a low-power microscopic
field (×10) as follows: 0, absent; 1, slight (only thin
neurites or small dots less than 12.5 μm in diameter);
2, mild (1–2 intraneuronal cytoplasmic bodies [ICBs]
or neurites or dots greater than 12.5 μm in diameter
[larger neurites]); 3, moderate (3–5 ICBs or larger
neurites); 4, severe (6 or more ICBs or larger neurites).
Larger neurites or dots with a diameter greater than
12.5 μm were quantitatively considered to be equiva-
lent to ICBs.
The degree (density score) of LBAS in the brain was
based on the third report of the Dementia with Lewy Bod-
ies Consortium [27] as follows: 0, absent; 1, only neurites; 2,
1–3 ICBs; 3, more than 4 ICBs; 4, numerous ICBs filled
with extensive immunoreactivity in the neuropil.
Statistical analysis
Statistical analyzes were performed with the PASW Sta-
tistics 18 software (SPSS Japan, Inc.). For multiple com-
parisons, the Friedman’s chi-square test was used,
followed by the Wilcoxon t-test with Bonferroni correc-
tion as a post-hoc analysis. Correlations between regions
were assessed with Spearman’s correlation analysis. The
McNemar test was used to test the difference between
paired proportions. P < 0.05 was considered statistically
significant.
Results
LBAS in the spinal cord versus in the brain
An additional file shows the clinicopathological charac-
teristics of the 265 subjects who had LBAS in at least
one of the sampled anatomical regions [see Additional
file 1: Table S1].
When LBAS was present in the spinal cord, all sub-
jects had LBAS in the brain (n = 173) (Table 1). No
subject had LBAS in the spinal cord without LBAS in
the brain (P < 0.001).
LBAS in the spinal cord versus in the brainstem or
olfactory bulb plus amygdala
Subjects with LBAS in the brainstem also had LBAS in
the spinal cord (87 % [174/200], P < 0.001) (Table 2). All
subjects with LBAS in the spinal cord also had LBAS in
the brainstem. Subjects lacking LBAS in the brainstem in-
variably failed to show LBAS in the spinal cord (Table 2).
Subjects with LBAS in the olfactory bulb plus amyg-
dala (n = 159) had LBAS in the spinal cord (68.5 % [159/
232], P = 0.009) (Table 3), and all of those 159 subjects
also had LBAS in the brainstem.
Of the 16 subjects with LBAS in the brainstem but
neither in the olfactory bulb nor amygdala, 12 (75 %)
had LBAS in the spinal cord. In contrast, subjects with
LBAS in the olfactory bulb and amygdala but not in the
brainstem (n = 51) invariably failed to show LBAS in the
spinal cord.
LBAS density score in the S2 dorsal horn versus in
the medullary reticular formation, locus ceruleus, or
amygdala
There was a significant correlation (P < 0.001) between
LBAS density score for the S2 dorsal horn and that for
the medullary reticular formation or locus ceruleus in
the lower brainstem region (Spearman’s rank correlation
coefficient (rs), 0.867 and 0.825, respectively; Fig. 1a, b).
Spearman’s rank correlation coefficient of the comparison
between the LBAS density scores for the S2 dorsal horn
and the amygdala (rs = 0.602) was lower than that for the




LBAS in spinal cord (+) 173 0
(−) 77 15
LBAS Lewy body–related α-synucleinopathy
(+) subjects with LBAS
(−) subjects without LBAS
Table 2 Number of subjects with LBAS in the spinal cord or
brainstem, or both
LBAS in spinal cord
(+) (−)
LBAS in brainstem (+) 174 26
(−) 0 65
LBAS Lewy body–related α-synucleinopathy
(+) subjects with LBAS
(−) subjects without LBAS
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comparison between the LBAS density scores for the S2
dorsal horn and the medullary reticular formation (rs =
0.867) or locus ceruleus (rs = 0.825) (Fig. 1c). Most subjects
with LBAS in the medullary reticular formation or locus
ceruleus (Fig. 1c, open circles) had LBAS in the S2 dorsal
horn. In contrast, subjects lacking LBAS in the medullary
reticular formation and locus ceruleus (Fig. 1c, closed trian-
gles) failed to show LBAS in the S2 dorsal horn.
Histology of LBAS in the primary sensory neurons
LBAS in the dorsal horn (Fig. 2a) and dorsal root (Fig. 2g)
was mainly composed of Lewy neurites. LBAS in the DRG
showed Lewy neurites (Fig. 2b), intracytoplasmic, diffuse,
granular immunoreactivity (pre-inclusion) (Fig. 2c), ICBs
(Fig. 2d, e), or Lewy bodies (Fig. 2f).
Distribution of LBAS in the primary sensory neurons
Table 4 shows the distribution of LBAS in the primary
sensory neurons. Subjects with LBAS in the DRG con-
sistently had LBAS in both the dorsal root and dorsal
horn at all lumbosacral levels (e.g., 100 %; 43/43 and 43/
43, respectively, in S2). Similarly, all subjects with LBAS
in the dorsal root also had LBAS in the dorsal horn
(100 %; 90/90, 20/20, 77/77, and 55/55 in S2, S1, L5, and
L2, respectively). In contrast, no LBAS was observed in
either the DRG or dorsal root when the dorsal horn was
not involved (e.g., 0 %; 0/110 and 0/110 in the DRG and
dorsal root, respectively, in S2). LBAS was not observed
in the DRG when the dorsal root was not involved (e.g.,
0 %; 0/171 in S2), except for in one subject (L2; 1/170).
LBAS in the sympathetic ganglia and Th-IML
There was a strong correlation between LBAS density
score in the sympathetic ganglia and that in the Th-IML
(rs = 0.879, P < 0.001, Fig. 3). When LBAS was present in
the Th-IML, all subjects had LBAS in the sympathetic
ganglia (Fig. 3).
Of 222 subjects whom both the sympathetic ganglia and
Th-IML were sampled, 12 (5.4 %) had LBAS in the sympa-
thetic ganglia, even in the absence of LBAS in the whole
brain. Of these 12 subjects, three had LBAS in the Th-IML.
Of these three subjects, one had LBAS only in the Th-IML
and not in any other region of the spinal cord.
Intersegmental comparison of LBAS density in the
spinal cord
Comparing the density score of LBAS in the dorsal
horn among four segments (cervical, thoracic, lumbar,
and sacral) of the spinal cord, we found a caudo–rostral
gradient in which the greatest LBAS density score was
at the sacral level followed by the lumbar, thoracic, and
cervical levels (Fig. 4a). Similar results were obtained in
the ventral horn (Fig. 4b) and intermediate zone (Fig. 4c).
LBAS in large motor neurons
In the ventral horn, not only Lewy neurites, but also LBAS
in the cell soma of the large motor neurons was observed
(Fig. 2h–j). In symptomatic subjects (Parkinson’s disease
and dementia with Lewy bodies) (n = 55) only, the fre-
quency of ICBs in the large motor neurons was 27.3,
21.8, 23.6 and 63.6 % in C8, Th8, L5, and S2, respect-
ively (Additional file 2: Figure S1).
LBAS in the Sa-IML
Of 261 subjects examined, no subject had LBAS that
was limited to the Sa-IML. Those with LBAS in the Sa-
IML also had LBAS in other sites of the spinal cord.
Discussion
In the present study, we examined the distribution of
LBAS in the spinal cord, primary sensory neurons, and
preganglionic sympathetic nerves in a consecutive series
of elderly autopsy subjects. Our results suggest that 1)
the presence of LBAS in specific regions of the lower
brainstem (i.e., the medullary reticular formation and
locus ceruleus) is strongly correlated with the presence
of LBAS in the spinal cord, whereas the presence of
LBAS in the spinal cord is independent of the presence
of LBAS in the olfactory bulb and amygdala; 2) LBAS
propagates retrogradely from the dorsal horn to the
DRG through the dorsal root; 3) LBAS propagates retro-
gradely from the sympathetic ganglia to the Th-IML;
and 4) LBAS in the spinal cord predominantly accumu-
lates at the caudal level.
Association between LBAS in the spinal cord and that in
the brainstem or amygdala
Here we found that LBAS develops first in the brain be-
fore developing in the spinal cord, which is consistent
with the findings of a previous study [20]. We found
that LBAS in the spinal cord was associated with LBAS
in the medullary reticular formation and locus ceruleus.
Previous studies have revealed the existence of direct
connectivity via projecting neurons between the spinal
cord and the medullary reticular formation and locus
Table 3 Number of subjects with LBAS in the spinal cord or
olfactory bulb plus amygdala
LBAS in spinal cord
(+) (−)
LBAS in olfactory bulb plus amygdala (+) 159 73
(−) 15 18
LBAS Lewy body–related α-synucleinopathy
(+) subjects with LBAS
(−) subjects without LBAS
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ceruleus, but not the amygdala [23–26, 33, 34]. Our
findings support the hypothesis of Del Tredici and
Braak in which LBAS in the spinal cord descends from
the supraspinal medullary reticular formation, locus
ceruleus, and raphe nucleus via projecting neurons
(Fig. 5a) [20]. In addition, we revealed a novel finding
that LBAS in the spinal cord is not correlated with
LBAS in the olfactory bulb and amygdala. When LBAS
follows the olfactory bulb–amygdala pathway and de-
velops downward through the spinal cord, the lower
brainstem is likely a key structure, implying that in
Lewy body disease that is following the olfactory bulb–
Fig. 1 Correlation between LBAS density in specific regions of the brain and in the S2 dorsal horn. Correlation between LBAS density in the
medullary reticular formation (a), locus ceruleus (b), or amygdala (c) and in the S2 dorsal horn. Each symbol represents one subject. A density
score of 1 or more indicates the deposition of LBAS, with increasing density score indicating greater deposition. Correlation was assessed by
calculating Spearman’s rank correlation coefficient. c Most subjects with LBAS in the medullary reticular formation or locus ceruleus (open circles)
had LBAS in the S2 dorsal horn (S2 dorsal horn density score ≥1). Even when the amygdala showed a higher degree of LBAS (density score 3 or
4), subjects who lacked LBAS in the medullary reticular formation and locus ceruleus (closed triangles) failed to show LBAS in the S2 dorsal horn
(S2 dorsal horn density score = 0). LBAS, Lewy body–related α-synucleinopathy
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amygdala pathway, LBAS primarily develops in the
amygdala and then gradually spreads to the lower
brainstem and finally the spinal cord.
LBAS in primary sensory neurons and preganglionic
sympathetic nerves
The present study is the first to evaluate how LBAS
spreads in primary sensory neurons. The dorsal root is
composed of axons derived from the DRG. LBAS
primarily develops in the dorsal horn and then spreads
to the DRG though the dorsal root (i.e., central-to-
peripheral spreading) (Fig. 5b).
Regarding the preganglionic sympathetic nerves, the
sympathetic ganglia may be one of the starting points
for LBAS development, and LBAS may propagate from
the sympathetic ganglia to the Th-IML (i.e., peripheral-
to-central spreading) (Fig. 5c).
Our results suggest that LBAS spreads retrogradely
through the primary sensory neurons and preganglionic
sympathetic nerves, which is plausible because the axonal
development of LBAS precedes perikaryal aggregation
[35–39]. Indeed, LBAS has already been shown to spread
retrogradely in cardiac postganglionic sympathetic nerves
(Fig. 5§) [2]. Recent in vivo studies have revealed that
Fig. 2 Photomicrographs of paraffin-embedded sections of spinal cord and primary sensory neurons. a Sacral dorsal horn of a subject with dementia with
Lewy bodies containing numerous LBAS deposits. b–e Lewy neurites (b), neuronal cytoplasmic diffuse granular appearance (c), and intraneuronal
cytoplasmic bodies (d, e) in the dorsal root ganglia of subjects with dementia with Lewy bodies. f Lewy body in the dorsal root ganglia of a subject with
Parkinson’s disease. g Proximal portion of the cervical dorsal root showing a swollen neurite (arrow). h–j LBAS in large motor neurons of the ventral horn
of subjects with dementia with Lewy bodies. Neuronal cytoplasmic diffuse granular appearance (h, i) and intraneuronal cytoplasmic body (j).
Phosphorylated α-synuclein immunohistochemical staining (a–e, g–j) or hematoxylin and eosin (f). scale bar = 100 μm for (a, g); 20 μm
for (b–f, h–j). LBAS, Lewy body–related α-synucleinopathy
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LBAS also spreads retrogradely along the vagus nerve
from the gut [40], and along the dopaminergic neurons in
the nigrostriatal system [41]. In the olfactory nervous
system, LBAS spreads both anterogradely (Fig. 5¶) and
retrogradely from the periphery of the olfactory bulb to
interconnected regions [16, 18, 33, 42]. Whether retrograde
spread alone explains the Lewy body disease process needs
to be further examined.
Caudo–rostral gradient in the spinal cord
The amount of LBAS in the spinal gray matter
showed a caudo–rostral gradient, which is consistent
with previous descriptions [3, 20, 22]. The precise
reason for this gradient is unclear, but may well be
ascribed to 1) a selective caudo–rostral vulnerability
to pathologic α-synuclein accumulation, or 2) the sa-
cral segment having a higher amount of endogenous α-sy-
nuclein. Lewy neurites may play a direct role in peripheral
nerve damage [43–45]. Parkinson’s disease patients often
suffer from limb pain, especially in the lower limbs, which
is localized to the anatomical territory of a peripheral
nerve or nerve root [46–49]. The development of LBAS in
primary sensory neurons and the development of the
caudo-rostral gradient may be associated with sensory dis-
orders in Parkinson’s disease patients.
LBAS in large motor neurons
LBAS in the large motor neurons preferentially accu-
mulated at the lower level of the spinal cord. Recent
studies indicate the subclinical denervation especially
in the lower limbs in Parkinson’s disease [50, 51]. It
remains unclear whether LBAS propagates anterogradely
or retrogradely in large motor neurons. One experimental
study has shown retrograde spread of LBAS into the
spinal cord via the peripheral nerves in transgenic mice
Table 4 Distribution of LBAS in primary sensory neurons
S2 (n = 261) S1 (n = 46) L5 (n = 261) L2 (n = 225)
DRG Dorsal Dorsal DRG Dorsal Dorsal DRG Dorsal Dorsal DRG Dorsal Dorsal
(+) root (+) horn (+) (+) root (+) horn (+) (+) root (+) horn (+) (+) root (+) horn (+)
DRG (+) – 43/43 43/43 – 12/12 12/12 – 45/45 45/45 – 34/35 35/35
(100) (100) (100) (100) (100) (100) (97.1) (100)
(−) – 47/218 108/218 – 8/34 15/34 – 32/216 102/216 – 21/190 83/190
(21.6) (49.5) (23.5) (44.1) (14.8) (47.2) (11.1) (43.7)
Dorsal root (+) 43/90 – 90/90 12/20 – 20/20 45/77 – 77/77 34/55 – 55/55
(47.8) (100) (60) (100) (58.4) (100) (61.8) (100)
(−) 0/171 – 61/171 0/26 – 7/26 0/184 – 70/184 1/170 – 63/170
(0) (35.7) (0) (26.9) (0) (38) (0.6) (37.1)
Dorsal horn (+) 43/151 90/151 – 12/27 20/27 – 45/147 77/147 – 35/118 55/118 –
(28.5) (59.6) (44.4) (74) (30.6) (52.4) (29.7) (46.6)
(−) 0/110 0/110 – 0/19 0/19 – 0/114 0/114 – 0/107 0/107 –
(0) (0) (0) (0) (0) (0) (0) (0)
Percentage of cases is given in parentheses
DRG Dorsal root ganglion, LBAS Lewy body-related α-synucleinopathy
(+) subjects with LBAS
(−) subjects without LBAS
Fig. 3 Correlation between the LBAS density for the Th-IML and that
for the sympathetic ganglia. Each symbol represents one subject. A
density score of 1 or more indicates the deposition of LBAS, with
increasing density score indicating greater deposition. Subjects who
had LBAS in the Th-IML (density score for the Th-IML ≥1) invariably
showed LBAS in the sympathetic ganglia (density score for the
sympathetic ganglia ≥1). Correlation was assessed by calculating
Spearman’s rank correlation coefficient. LBAS, Lewy body–related
α-synucleinopathy
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who received intramuscular injection of pathogenic α-
synuclein [52].
LBAS in Sa-IML
Given the early development of gastrointestinal abnormal-
ities in Lewy body disease [53–56], we hypothesized that
the Sa-IML would be one of the initial sites where LBAS
develops through the preganglionic parasympathetic nerves
from pelvic organs such as the descending colon or rectum
(Fig. 5d) [15, 57]. However, we did not find any subject har-
boring LBAS exclusively in the Sa-IML. One reason for this
may be that the S2 level we examined contains fewer neu-
rons than the S3–5 levels, which reduced the potential for
detecting LBAS in the Sa-IML. Further, investigation of
both the pelvic organs and Sa-IML will be important to
clarify whether an alternative pattern of LBAS propagation,
in which LBAS originates in the Sa-IML before spreading
to the entire spinal cord, exists or not.
Future direction
The findings of the present neuropathological examin-
ation should be interpreted with caution because these
results do not mean that LBAS in the spinal cord always
originates from outside the spinal cord. Some LBAS in
the spinal cord may be derived from single or multiple
sites within the spinal cord. Furthermore, the study
cohort included only elderly subjects and therefore the
results may not be generalizable to younger populations.
Our neuropathological assessment did not allow us to
see the actual process of LBAS propagation within a
neuron; therefore, clinicopathological studies are re-
quired to establish a causal relationship between LBAS
and peripheral nerve disorders in Lewy body diseases.
Conclusion
LBAS in the spinal cord was associated with the lower re-
gions of the brainstem but was not associated with the ol-
factory bulb and amygdala. LBAS may spread centrifugally
Fig. 4 Comparison of LBAS density at different levels of the spinal cord. The degree of LBAS among four different segments (cervical, thoracic, lumbar,
and sacral) in three different regions (dorsal horn, ventral horn, and intermediate zone) of the spinal gray matter showed a caudo–rostral gradient in
which the greatest was at the sacral level followed by the lumbar, thoracic, and cervical levels. a Dorsal horn (Rexed lamina I–VI, n = 256). b Ventral
horn (Rexed lamina VIII–IX, n = 258). c Intermediate zone (Rexed lamina VII and X, n = 258). * P < 0.01
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along the primary sensory neurons, whereas it may spread
centripetally along the preganglionic sympathetic nerves.
Further study of the progressive spread of LBAS in con-
nected neuronal systems will assist in clarifying the precise
progression of the Lewy body diseases.
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